Table 1.
Patient characteristics of STS and LTS | ||
---|---|---|
STS; n = 50 | LTS; n = 5O | |
Age (years) |
64, 8 |
51, 9 |
< 60 years |
16 (32) |
35 (60) |
> 60 years |
34 (68) |
15 (30) |
< 70 years |
34 (68) |
43 (86) |
> 70 years |
16 (32) |
7 (14) |
Male |
33 (66) |
26 (52) |
Female |
17 (34) |
24 (48) |
Tumor location | ||
Right hemisphere |
16 (32) |
24 (48) |
Left hemisphere |
24 (48) |
23 (46) |
Both hemispheres |
10 (20) |
3 (6) |
Location close to the ventricle (< 10 mm) |
44 (88) |
33 (68, 8) |
Location distant to the ventricle (≥ 10 mm) |
6 (12) |
15 (31, 3) |
Involvement of the ventricle system |
30 (60) |
18 (39, 1) |
Multifocal disease |
12 (24) |
7 (15, 2) |
Subependymal spread |
15 (30) |
5 (10, 9) |
Extent of resection | ||
Biopsy |
26 (52) |
5 (10, 4) |
Total resection |
7 (14) |
22 (45,8) |
Partial resection |
17 (34) |
22 (45,8) |
Ventricle opening during surgery |
8 (16) |
17 (34,7) |
Classification (Lim et al.) | ||
Type I |
18 (36) |
21 (43,8) |
Type II |
16 (32) |
6 (12, 5) |
Type llI |
9 (18) |
15 (31, 3) |
Type IV |
7 (14) |
6 (125) |
MGMT hypermethyation |
4 (36, 4) |
12 (70, 6) |
Radiotherapy within a study |
23 (46) |
25 (50) |
GD (Gy) |
56, 8 |
45, 1 |
RT as Re-irradiation |
3 (6) |
15 (30) |
Radiochemotherapy |
35 (70) |
38 (76) |
Temozolomide | 32 (64) | 35 (70) |
Numbers in brackets represent percentages and refer to the absolute values in front.